Table 2.
The diagnostic performance of a beta-glucan test for identifying intra-amniotic Candida infection
| Study population (n=197) | Women with IUD (n=58) | Women without IUD (n=139) | ||||
|---|---|---|---|---|---|---|
| % (n) | 95% CI | % (n) | 95% CI | %(n) | 95% CI | |
| Frequency of Candida intra-amniotic infection | 10.2% (20/197) | 6.3%–15.2% | 15.5% (9/58) | 7.4%–27.4% | 7.9% (11/139) | 4.0%–13.7% |
| Sensitivity | 95.0% (19/20) | 75.1%–99.9% | 100.0% (9/9) | 63.4%–100.0% | 90.9% (10/11) | 58.7%–99.7% |
| Specificity | 75.1% (133/177) | 68.1%–81.3% | 32.7% (16/49) | 20.0%–47.5% | 91.4% (117/128) | 85.1%–95.6% |
| Positive likelihood ratio | 3.8 | 2.9–5.0 | 1.5 | 1.2–1.8 | 10.6 | 5.8–19.2 |
| Negative likelihood ratio | 0.1 | 0.01–0.5 | 0.0 | 0.1 | 0.02–0.7 | |
| Positive predictive value | 30.2% (19/63) | 24.7%–36.3% | 21.4% (9/42) | 18.3%–24.9% | 47.6% (10/21) | 33.4%–62.2% |
| Negative predictive value | 99.3% (133/134) | 95.2%–99.9% | 100.0% (16/16) | 99.2% (117/118) | 94.7%–99.9% | |
LEGEND. CI: confidence interval; IUD: intrauterine contraceptive device.